A detailed history of Fred Alger Management, LLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Fred Alger Management, LLC holds 4,119,394 shares of CABA stock, worth $10.8 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
4,119,394
Previous 2,522,882 63.28%
Holding current value
$10.8 Million
Previous $18.9 Million 3.03%
% of portfolio
0.1%
Previous 0.09%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.94 - $8.24 $6.29 Million - $13.2 Million
1,596,512 Added 63.28%
4,119,394 $19.4 Million
Q2 2024

Aug 14, 2024

SELL
$7.22 - $18.82 $4.24 Million - $11.1 Million
-587,432 Reduced 18.89%
2,522,882 $18.9 Million
Q1 2024

May 15, 2024

SELL
$16.79 - $25.38 $3.64 Million - $5.5 Million
-216,818 Reduced 6.52%
3,110,314 $53.1 Million
Q4 2023

Feb 14, 2024

SELL
$12.21 - $23.36 $11.4 Million - $21.8 Million
-932,323 Reduced 21.89%
3,327,132 $75.5 Million
Q3 2023

Nov 14, 2023

SELL
$11.84 - $18.65 $3.71 Million - $5.85 Million
-313,431 Reduced 6.85%
4,259,455 $64.8 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $4.27 Million - $7.78 Million
557,576 Added 13.89%
4,572,886 $59 Million
Q1 2023

May 15, 2023

BUY
$7.08 - $12.62 $23.2 Million - $41.4 Million
3,279,361 Added 445.6%
4,015,310 $33.2 Million
Q4 2022

Feb 14, 2023

BUY
$0.64 - $9.3 $471,007 - $6.84 Million
735,949 New
735,949 $6.81 Million
Q4 2021

Feb 14, 2022

SELL
$3.36 - $14.64 $721,462 - $3.14 Million
-214,721 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.0 - $12.5 $1.5 Million - $2.68 Million
214,721 New
214,721 $2.61 Million

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $76M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.